Hark back: Passive immunotherapy for influenza and other serious infections

Critical Care Medicine

Volumn 38, Issue SUPPL. 4, 2010, Pages

  Luke, Thomas C ^a   Casadevall, Arturo ^b   Watowich, Stanley J ^c   Hoffman, Stephen L ^d   Beigel, John H ^e   Burgess, Timothy H ^a  

^a NAVAL MEDICAL RESEARCH CENTER   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^d Protein Potential LLC   (United States)

^e NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Antibody; Convalescent; Immunoglobulin; Immunotherapy; Influenza; Passive; Plasma; Serum

Indexed keywords

FRESH FROZEN PLASMA; HYPERIMMUNE GLOBULIN; INFLUENZA VACCINE; OSELTAMIVIR;

APHERESIS; CONVALESCENCE; CYTOMEGALOVIRUS; DISEASE SEVERITY; DRUG EFFICACY; EBOLA VIRUS; FOOD AND DRUG ADMINISTRATION; HAEMOPHILUS INFLUENZAE; HEPATITIS A; HEPATITIS B; HUMAN; IMMUNOTHERAPY; INFLUENZA; INFLUENZA VACCINATION; MORBIDITY; MORTALITY; NONHUMAN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; PUBLIC HEALTH; RABIES; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; REVIEW; UNITED STATES; VACCINIA VIRUS;

EID: 77950219752     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e3181d44c1e     Document Type: Article

References (113)

1. Cohen J: Public health. A race against time to vaccinate against novel H1N1 virus. Science 2009; 325:1328-1329
2. Advisory Committee on Immunization Practices: Use of Influenza A (H1N1) 2009 Monovalent Vaccine. Recommendations of the Advisory Committee on Immunization Practices, 2009. Available at http://www.cdc. gov/mmwr/preview/ mmwrhtml/rr58e0821al. htm. Accessed September 30, 2008
3. Centers for Disease Control and Prevention, Influenza Division: Fluview: A weekly influenza surveillance report: 2009-2010 influenza season week 3 ending January 23, 2010. Centers for Disease Control and Prevention, January 29, 2010. Available at http://www.cdc.gov/flu/weekly. Accessed February 2, 2010
4. World Health Organization: Pandemic (H1N1) 2009: Update 60. Geneva, Switzerland, World Health Organization, July 31, 2009. Available at www.who.int/csr/don/2009-08-04/en/index.html. Accessed Sept 30, 2009
5. Centers for Disease Control and Prevention: Oseltamivir-resistant 2009 pandemic influenza A (H1N1) virus infection in two summer campers receiving prophylaxis-North Carolina, 2009. MMWR Morb Mortal Wkly Rep 2009; 58:969-972
6. Centers for Disease Control and Prevention: Updated interim recommendations for the use of antiviral medications in the treatment and prevention of influenza for the 2009-2010 season. Centers for Disease Control and Prevention, December 7, 2009. Available at http://www.cdc.gov/h1n1flu/ recommendations.htm. Accessed September 30, 2009
7. World Health Organization: Global Alert and Response (GAR): Antiviral use and the risk of drug resistance. World Health Organization, September 31, 2009. Available at http://www. who.int/csr/disease/swineflu/notes/h1n1- antiviral-use-20090925/en/index.html. Accessed September 30, 2008
8. Centers for Disease Control and Prevention: Interim antiviral guidance for 2008-2009. Centers for Disease Control and Prevention, July 1, 2009. Available at http://www.cdc. gov/flu/professionals/antivirals/index.htm. Accessed September 30, 2009
9. Dharan NJ, Gubareva LV, Meyer JJ, et al: Infections with oseltamivir-resistant influenza A (H1N1) virus in the United States. JAMA 2009; 301:1034-1041
10. World Health Organization, Blood Regulators Network: Position paper on collection and use of convalescent plasma or serum as an element in pandemic influenza planning. World Health Organization, July 9, 2009. Available at www.who.int/bloodproducts/brn/en/. Accessed September 30, 2009
11. Casadevall A, Scharff MD: Return to the past: the case for antibody-based therapies in infectious diseases. Clin Infect Dis 1995; 21:150-161
12. Buchwald UK, Pirofski L: Immune therapy for infectious diseases at the dawn of the 21st century: The past, present and future role of antibody therapy, therapeutic vaccination and biological response modifiers. Curr Pharm Des 2003; 9:945-968
13. Stoll HF: Value of convalescent blood and serum in treatment of influenza pneumonia. JAMA 1919; 73:478-483
14. O'Malley JJ, Hartman FW: Treatment of influenzal pneumonia with plasma of convalescent patients. JAMA 1919; 72:34-37
15. Ross CW, Hund EJ: Transfusion on the desperate pneumonias complicating influenza-Preliminary report on the successful use of total immune citrated blood. JAMA 1918; 71:1992-1993
16. Ross CW, Hund EJ: Treatment of pneumonic disturbance complicating influenza. JAMA 1919; 72:640-645
17. Kahn MH: Serum treatment of postinfluenzal bronchopneumonia. JAMA 1919; 72: 102-103
18. Gould EW: Human serum in the treatment of influenza bronchopneumonia. NY Med J 1919; 109:666-667
19. McGuire LW, Redden WR: Treatment of influenzal pneumonia by the use of convalescent human serum-Preliminary report. JAMA 1918; 71:1311
20. McGuire LW, Redden WR: Treatment of influenzal pneumonia by the use of convalescent human serum. JAMA 1919; 72: 709-713
21. Sanborn GP: The use of the serum of convalescents in the treatment of influenza pneumonia: A summary of the results in a series of one hundred and one cases. Boston Med Surg J 1920; 183:171-177
22. Maclachlan WW, Fetter WJ: Citrated blood in treatment of the pneumonia following influenza. JAMA 1918; 71:2053-2055
23. Francis FD, Hall MW, Gaines AR: Early use of convalescent serum in influenza. Mil Surg 1920; 47:177-179
24. Redden WR: Treatment of influenzapneumonia by use of convalescent human serum. Boston Med Surg J 1919; 161: 688-691
25. Jacobaeus: Treatment of influenza pneumonia with serum from convalescents. Svenska Lakartidnin 1920; 18:385-399
26. Bass JA, Ervin CE: Use of serum in the treatment of influenza-pneumonia. Naval Med Bull 1919; 71-73
27. Simici D: Treatment of influenza with injections of blood from convalescents. Paris Med 1922; 43:474-477
28. Hoist J: Convalescent serum in treatment of influenza. Norsk Magazine for Laegevidenskaben 1919; 80:531-561
29. Lesne E, Brodin P, Saint-Girons F: Plasma therapy in influenza. Presse Med 1919; 27: 181-182
30. Ehrenberg L, Barkman A: Convalescent serum in the prevention and treatment of influenza. Hygiea 1919; 81:113-123
31. Bag O: Convalescent serum in the treatment of influenza pneumonia. Norsk Magazine Laegevidenskaben 1920; 81:255-261
32. Bogardus FB: Influenza pneumonia treated by blood transfusions. NY Med J 1919; 109: 765
33. Huff-Hewitt WE: Human serum in influenza. Br Med J 1919; 1:575
34. Miller OO, McConnell WT: Report of influenza treated with serum from recovered cases. Ky Med J 1919; 17:218-219
35. Brown WL, Sweet BL: Treatment of influ-enzal pneumonia by citrated transfusions. JAMA 1918; 71:1602-1603
36. Carlyle PM: Injection of whole blood in influenza. Br Med J 1919; 1:698
37. Luke TC, Kilbane EM, Jackson JL, et al: Meta-analysis: Convalescent blood products for Spanish influenza pneumonia: A future H5N1 treatment? Ann Intern Med 2006; 145:599-609
38. Berezina AI: [Experience in treating influenza with dry anti-influenza serum of Smorodintsev; preliminary report.] Sov Med 1956; 20:67-68
39. Stavskaia W, Ignateva NA: [On the treatment of influenza and influenzal pneumonia.] Klin Med (Mosk) 1963; 41:69-75
40. Selivanov AA, Morozenko MA, Kallas EV, et al: [Experimental for achievement of therapeutic sera against respiratory infections from immunized donors]. Vrach Delo 1967; 1:104-106
41. Zhukova EA: [Character of the therapeutic action of different schedules of administration of donor anti-influenza gammaglobulin to influenza patients]. Tr Inst Im Pastera 1985; 63:47-51
42. Firsov SL, Zhukova EA: [Experience with the clinical use of donor anti-influenza gamma-globulin]. Tr Inst Im Pastera 1985; 63:52-55
43. Sweet C, Jakeman KJ, Smith H: Role of milk-derived IgG in passive maternal protection of neonatal ferrets against influenza. J Gen Virol 1987; 68:2681-2686
44. Sweet C, Bird RA, Jakeman K, et al: Production of passive immunity in neonatal ferrets following maternal vaccination with killed influenza A virus vaccines. Immunology 1987; 60:83-89
45. McClure JT, DeLuca JL, Lunn DP, et al: Evaluation of IgG concentration and IgG subisotypes in foals with complete or partial failure of passive transfer after administration of intravenous serum or plasma. Equine Vet J 2001; 33:681-686
46. Zhang F, Chen J, Fang F, et al: Maternal immunization with both hemagglutininand neuraminidase-expressing DNAs provides an enhanced protection against a lethal influenza virus challenge in infant and adult mice. DNA Cell Biol 2005; 24:758-765
47. Reuman PD, Ayoub EM, Small PA: Effect of passive maternal antibody on influenza illness in children: A prospective study of influenza A in mother-infant pairs. Pediatr Infect Dis J 1987; 6:398-403
48. Englund JA, Mbawuike IN, Hammill H, et al: Maternal immunization with influenza or tetanus toxoid vaccine for passive antibody protection in young infants. J Infect Dis 1993; 168:647-656
49. Virelizier JL: Host defenses against influenza virus: the role of anti-hemagglutinin antibody. J Immunol 1975; 115:434-1139
50. Takiguchi K, Sugawara K, Hongo S, et al: Protective effect of serum antibody on respiratory infection of influenza C virus in rats. Arch Virol 1992; 122:1-11
51. Mozdzanowska K, Furchner M, Washko G, et al: A pulmonary influenza virus infection in SCID mice can be cured by treatment with hemagglutinin-specific antibodies that display very low virus-neutralizing activity in vitro. J Virol 1997; 71:4347-4355
52. Lu J, Guo Z, Pan X, et al: Passive immunotherapy for influenza A H5N1 virus infection with equine hyperimmune globulin F(ab')2 in mice. Respir Res 2006; 7:43
53. Treanor J: Avian influenza: Exploring all the avenues. Ann Intern Med 2006; 145: 631-632
54. U.S. Food and Drug Administration (FDA): FDA, Code of Federal Regulations, CFR600 series, CFR210 series, and CFR211 series (and others that apply). Available at http://www.gpoaccess.gov/CFR/. Accessed September 30, 2009
55. U.S. Food and Drug Administration: CPG Sec. 252.110 Volume Limits for Automated Collection of Source Plasma (03/06/2000 New). Available at http://www.fda.gov/ICECI/ComplianceManuals/CompliancePolicyGuidanceManual/ ucm073874.htm. Accessed September 30, 2009
56. Weinstein SM: Principles and Practice of Intravenous Therapy. Eighth Edition. Philadelphia, PA, Lippincott Williams & Wilkins, 2007, pp 429
57. U.S. Food and Drug Administration: Code of Federal Regulations, Frequency of Whole Blood Collection, 21 CFR Part 640.3 57.(f). Available at http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm. Accessed February 2, 2010
58. Walter CW: Development of plastic equipment for blood bank use. Bibl Haematol 1958; 7:491-495
59. Walter CW: Invention and development of the blood bag. Vox Sang 1984; 47:318-324
60. American Association of Blood Banks: Accredited Blood Banks, Transfusion Services, and Blood Centers. Available at http://www. aabb.org/Content/ Accreditation/AABB- Accredited-Blood-Banks-Transfusion- Services-and-Blood- Donor-Centers/ accredlisting.htm. Accessed September 30, 2009
61. American Red Cross: Local Red Cross Blood Services Regions. Available at http://www. givelife2.org/links.asp. Accessed September 30, 2009
62. America's Blood Centers. Available at http://www.americasblood.org/go. cfm?do=Page. View&pid=29. Accessed September 30, 2009
63. Plasma Protein Therapeutics Association: Plasma & blood. Available at http://www. pptaglobal.org/plasma/plasma-vs-blood. aspx. Accessed September 30, 2009
64. Hellstern P, Muntean W, Schramm W, et al: Practical guidelines for the clinical use of plasma. Thromb Res 2002; 107(Suppl 1): S53-S57
65. O'Shaughnessy DF, Atterbury C, BoltonMaggs P, et al: Guidelines for the use of fresh-frozen plasma, cryoprecipitate and cryosupernatant. Br J Haematol 2004; 126: 11-28
66. McGuinness AC, Stokes J, Mudd S: The clinical uses of human serum preserved by the lyophile process. J Clin Invest 1937; 16: 185-196
67. Casadevall A, Scharff MD: "Serum Therapy" revisited: Animal models of infection and the development of passive antibody therapy. Antimicrob Agents Chemotherap 1994; 38:1695-1702
68. Bunim BJ, Wies FA: The use of fresh human serum (complement) in meningococcus meningitis. JAMA 1933; 100:178-180
69. Fothergill LRD: Hemophilus influenzae (Pfeiffer bacillus) meningitis and its specific treatment. N Engl J Med 1937; 216:587-590
70. Fothergill LD, Wright J: Influenzal meningitis: The relation of age incidence to the bactericidal power of blood against the causal organism. J Immunol 1933; 24: 273-284
71. Birkhaug KE: Studies in scarlet fever. II. Studies on the use of convalescent scarlet fever serum and Dochez antistreptococcic serum for the treatment of scarlet fever. Bull Johns Hopkins Hosp 1925; 36:134-171
72. Lapin JH: Serum in the prophylaxis of contact and the treatment of whooping cough. J Pediatr 1945; 26:555-559
73. Scheinblum IE, Bullowa JGM: The treatment of pertussis with lyophile hyperimmune human pertussis serum. J Pediatr 1944; 25:49-55
74. Balagtas RC, Nelson KE, Levin S, et al: Treatment of pertussis with pertussis immune globulin. J Pediatr 1971; 79:203-208
75. Wolf AM, Levinson SO: Human serum and plasma: their application in medicine. Med Clin North Am 1943; 157:175
76. Stokes J, Maris EP, Gellis SS: Chemical, clincical, and immunological studies on the products of human plasma fractionation XI. The use of concentrated normal human serum gamma globulin (human immune serum globulin) in the prophylaxis and treatment of measles. J Clin Invest 1944; 23: 531-540
77. Balfour HH Jr, Groth KE, McCullough J, et al: Prevention or modification of varicella using zoster immune plasma. Am J Dis Child 1977; 131:693-696
78. Brodie M: A comparison between convalescent serum and non-convalescent serum in poliomyelitis. J Exp Med 1932; 55:507-519
79. Enria DA, Briggile AM, Sanchez Z: Treatment of Argentine hemorrhagic fever antiviral research. Antiviral Res 2008; 78: 132-139
80. Zhou B, Zhong N, Guan Y: Treatment with convalescent plasma for influenza A (H5N1) infection. N Engl J Med 2007; 357:14:1451
81. Chen CY, Lee CH, Liu CY, et al: Clinical features and outcomes of severe acute respiratory syndrome and predictive factors for acute respiratory distress syndrome. J Chin Med Assoc 2005; 68:4-10
82. Wang JT, Sheng WH, Fang CT, et al: Clin-ical manifestations, laboratory findings, and treatment outcomes of SARS patients. Emerg Infect Dis 2004; 10:818-824
83. Ho JC, Wu AY, Lam B, et al: Pentaglobin in steroid-resistant severe acute respiratory syndrome. Int J Tuberc Lung Dis 2004; 8:1173-1179
84. Soo YO, Cheng Y, Wong R, et al: Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients. Clin Microbiol Infect 2004; 10:676-678
85. Cheng Y, Wong R, Soo YO, et al: Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis 2005; 24:44-46
86. Stockman LJ, Bellamy R, Garner P: SARS: Systematic review of treatment effects. PLoS Med 2006; 3:e343
87. Blick G, Scott WF, Crook SW, et al: Passive immunotherapy in advanced HIV infection and therapeutic plasmapheresis in asymptomatic HIV-positive individuals: a fouryear clinical experience. Biotherapy 1998; 11:7-14
88. Vittecoq D, Mattlinger B, Barre-Sinoussi F, et al: Passive immunotherapy in AIDS: a randomized trial of serial human immunodeficiency virus-positive transfusions of plasma rich in p24 antibodies versus transfusions of seronegative plasma. J Infect Dis 1992; 165:364-368
89. Vittecoq D, Chevret S, Morand-Joubert L, et al: Passive immunotherapy in AIDS: a double-blind randomized study based on transfusions of plasma rich in anti-human immunodeficiency virus 1 antibodies vs. transfusions of seronegative plasma. Proc Natl Acad Sci 1995; 92:1195-1199
90. Levy J, Youvan T, Lee ML: Passive hyperimmune plasma therapy in the treatment of acquired immunodeficiency syndrome: Results of a 12-month multicenter doubleblind controlled trial. The Passive Hyperimmune Therapy Study Group. Blood 1994; 84:2130-2135
91. Stiehm ER, Fletcher CV, Mofenson LM, et al: Use of human immunodeficiency virus (HIV) human hyperimmune immunoglobulin in HIV type 1-infected children (Pediatric AIDS clinical trials group protocol 273). J Infect Dis 2000; 181:548-554
92. Jahrling PB, Frame JD, Rhoderick JB, et al: Endemie Lassa fever in Liberia. IV. Selection of optimally effective plasma for treatment by passive immunization. Trans R Soc Trop Med Hyg 1985; 79:380-384
93. Jahrling PB, Geisbert JB, Swearengen JR, et al: Ebola hemorrhagic fever: evaluation of passive immunotherapy in nonhuman primates. J Infect Dis 2007; 196(Suppl 2): S400-S403
94. Nour B, Green M, Michaels M, et al: Parvovirus B19 infection in pediatric transplant patients. Transplantation 1993; 56: 835-838
95. Koduri PR, Kumapley R, Valladares J, et al: Chronic pure red cell aplasia caused by par-vovirus B19 in AIDS: Use of intravenous immunoglobulin-a report of eight patients. Am J Hematol 1999; 61:16-20
96. Reed EC, Bowden RA, Dandliker PS, et al: Treatment of cytomegalovirus pneumonia with ganciclovir and intravenous cytomegalovirus immunoglobulin in patients with bone marrow transplants. Ann Intern Med 1988; 109:783-788
97. Whimbey E, Champlin RE, Englund JA, et al: Combination therapy with aerosolized ribavirin and intravenous immunoglobulin for respiratory syncytial virus disease in adult bone marrow transplant recipients. Bone Marrow Transplant 1995; 16:393-399
98. DeVincenzo JP, Hirsch RL, Fuentes RJ, et al: Respiratory syncytial virus immune globulin treatment of lower respiratory tract infection in pediatric patients undergoing bone marrow transplantation - a compassionate use experience. Bone Marrow Transplant 2000; 25:161-165
99. Centers for Disease Control and Prevention: Medical management of smallpox (vaccinia) vaccine adverse reactions: Vaccinia immune globulin and cidofovir. Centers for Disease Control and Prevention, September 28, 2009. Available at http://www.bt.cdc.gov/agent/smallpox/vaccination/mgmt-adv- reactions. asp. Accessed September 30, 2009
100. Center for Disease Control and Prevention: Prevention of hepatitis A through active or passive immunization: Recommendations of the Advisory Committee on Immuniza-tion Practices (ACIP). MMWR Morb Mortal Wkly Rep 1999; 48:1-12
101. Stokes J, Neefe JR: The prevention and attenuation of infectious hepatitis by gamma globulin: Preliminary note. JAMA 1945; 127:144-145
102. Samuel D, Muller R, Alexander G, et al: Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 1993; 329:1842-1847
103. Engler S, Sauer P, Klar E, et al: Prophylaxis of hepatitis B recurrence after liver transplantation with lamivudin and hepatitis B immunoglobulin. Transplant Proc 2002; 34:2285-2287
104. Centers for Disease Control and Prevention: Human rabies prevention-United States, 2008. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2008; 57:1-28
105. Kudoyarova-Zubavichene NM, Sergeyev NN, Chepurnov AA, et al: Preparation and use of hyperimmune serum for prophylaxis and therapy of Ebola virus infections. J Infectais Dis 1999; 179(Suppl 1):S218-S223
106. Defense Health Board: Available at www. health.mil/dhb/default.cfm. Accessed September 30, 2009
107. Defense Health Board: Select Subcommittee on Infectious Diseases Control. Convalescent Plasma (CP) Therapy Guidelines. Defense Health Board Meeting of April 23-24, 2008. Available at http://www.health. mil/dhb/downloads/20080527/ Dr.%20 Clements%20Presentation-Convalescent% 20Plasma% 20 Recommendations.pdf. Accessed September 30, 2009
108. World Health Organization, Blood Regulators Network: Position paper on collection and use of convalescent plasma or serum as an element in pandemic influenza planning. Available at http://www.who.int/bloodproducts/brn/en/. Accessed September 30, 2009
109. National Institutes of Health: A pilot study for collection of anti-influenza A H1N1 (swine flu) hyper-immune plasma. ClinicalTrials.gov. 2009. U.S. National Institutes of Health, September 24, 2009. Available at http://clinicaltrials.gov/ct2/show/NCT00984451. Accessed September 30, 2009
110. Hewetson JF, Little SF, Ivins BE, et al: An in vivo passive protection assay for the evaluation of immunity in AVA-vaccinated individuals. Vaccine 2008; 26:4262-4266
111. Lucchesi PF, Gildersleeve N: The treatment of anthrax. JAMA 1941; 14:1506-1508
112. Casadevall A: Passive antibody administration (immediate immunity) as a specific defense against biological weapons. Emerg Infect Dis Aug 2002; 8:833-841
113. Department of Health and Human Services (HHS): HHS Pandemic Influenza Plan. Available at http://www.hhs.gov/pandemicflu/plan/appendixd.html. Accessed September 30, 2009